The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Charles J. Ryan
No relevant relationships to disclose
Matthew Raymond Smith
Consultant or Advisory Role - Cougar Biotechnology
Research Funding - Cougar Biotechnology
Johann Sebastian De Bono
Employment or Leadership Position - The Institute of Cancer Research
Consultant or Advisory Role - Johnson & Johnson
Arturo Molina
Employment or Leadership Position - Janssen research and development
Stock Ownership - Johnson & Johnson
Christopher Logothetis
Consultant or Advisory Role - Janssen Pharmaceutical ; Johnson & Johnson
Honoraria - Johnson & Johnson
Research Funding - Johnson & Johnson
Paul L. De Souza
Consultant or Advisory Role - Janssen Pharmaceutical
Karim Fizazi
Consultant or Advisory Role - Cougar Biotechnology; Janssen Pharmaceutical
Honoraria - Janssen Pharmaceutical
Paul N. Mainwaring
No relevant relationships to disclose
Jose Maria Piulats Rodriguez
No relevant relationships to disclose
Siobhan Ng
No relevant relationships to disclose
Joan Carles
No relevant relationships to disclose
Peter Mulders
Consultant or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; GlaxoSmithKline; Novartis; Pfizer
Thian San Kheoh
Employment or Leadership Position - Janssen research and development
Stock Ownership - Johnson & Johnson
Thomas W. Griffin
Employment or Leadership Position - Janssen research and development
Stock Ownership - Johnson & Johnson
Eric Jay Small
No relevant relationships to disclose
Howard I. Scher
Consultant or Advisory Role - Amgen; Aragon Pharmaceuticals (U); Bristol-Myers Squibb; Dendreon; Exelixis (U); Janssen Pharmaceutical (U); Medivation (U); Millennium; Novartis; Ortho Biotech; Sanofi ; Senior Scientific LLC
Research Funding - Aragon Pharmaceuticals; Bristol-Myers Squibb; Exelixis; Medivation; Ortho Biotech; Veridex
Dana E. Rathkopf
No relevant relationships to disclose